Loading stock data…
AVIR
$5.70+0.12 (+2.15%)
Market ClosedLast close May 4
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Atea Pharmaceuticals, Inc. in the Healthcare sector is trading at $5.70. The stock is currently near its 52-week high of $6.45, remaining 44.7% above its 200-day moving average. Technical signals show neutral RSI of 47 and bearish MACD signal, explaining why AVIR maintains its current momentum and trend strength. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 47) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$5.70
Potential Upside
5%
Whystock Fair Value$5.99
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus3 analysts
Buy
Mean target$8.83+55.0%
Range$6.00 – $10.50
Fundamentals
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucl...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$444.57M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.16
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-57.49%
Volume
Today's trading volume
355,705
Recent News
Atea Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary
Moby summary of Atea Pharmaceuticals, Inc.'s Q4 2025 earnings call
Atea Pharmaceuticals Inc (AVIR) Q4 2025 Earnings Call Highlights: Advancing HCV Treatments and ...
Atea Pharmaceuticals Inc (AVIR) showcases strong clinical progress and financial stability while navigating competitive challenges in the HCV treatment landscape.
Atea Pharmaceuticals Q4 Earnings Call Highlights
Atea Pharmaceuticals (NASDAQ:AVIR) outlined progress in its hepatitis C (HCV) late-stage development program and provided an update on its newly expanded hepatitis E virus (HEV) pipeline during its fourth quarter and full-year 2025 financial results conference call. Management also discussed commerc
CarMax Stock Down 47% This Past Year, But One Fund Is Betting $6 Million on a Turnaround
CarMax runs a nationwide network of used car stores and digital channels, offering multi-channel sales and financing to U.S. consumers.
Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.
This clinical-stage biotech develops therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition.